Furthermore, in breast cancer, SMYD3 drives cell cycle progression by upregulating the transcription of cyclin A1 [48] whereas, in hepatocellular carcinoma, SMYD3 promotes proliferation through stimulating CDK2 transcription [37]. Here, CDK2 is linked to breast cancer.